HLVX vs. SVRA, TECX, FULC, SLDB, PASG, PRTC, SNDL, ERAS, CMPX, and AQST
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Savara (SVRA), Tectonic Therapeutic (TECX), Fulcrum Therapeutics (FULC), Solid Biosciences (SLDB), Passage Bio (PASG), PureTech Health (PRTC), SNDL (SNDL), Erasca (ERAS), Compass Therapeutics (CMPX), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.
HilleVax vs. Its Competitors
HilleVax (NASDAQ:HLVX) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.
HilleVax has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.
HilleVax's return on equity of -51.86% beat Savara's return on equity.
HilleVax presently has a consensus price target of $2.00, suggesting a potential downside of 5.66%. Savara has a consensus price target of $5.60, suggesting a potential upside of 142.42%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than HilleVax.
Savara is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
86.4% of HilleVax shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 24.9% of HilleVax shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Savara had 1 more articles in the media than HilleVax. MarketBeat recorded 3 mentions for Savara and 2 mentions for HilleVax. Savara's average media sentiment score of 1.81 beat HilleVax's score of 1.44 indicating that Savara is being referred to more favorably in the news media.
Summary
Savara beats HilleVax on 8 of the 13 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HLVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
This page (NASDAQ:HLVX) was last updated on 7/17/2025 by MarketBeat.com Staff
Free HLVX Stock Alerts